Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates [Yahoo! Finance]
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.